|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Efficacy and safety of metformin and sitagliptin based triple antihyperglycemic therapy(STRATEGY):a multicenter,randomized,controlled,non-inferiority clinical trial显示文摘Despite the current guideline's recommendation of a timely stepwise intensification therapy,the 'clinical inertia',termed as the delayed treatment intensification,commonly exists in the real world,which may be partly due to the relatively little substantial evidence and no clear consensus regarding the efficacy and safety of triple oral agents in patients inadequately controlled with dual therapy.In this clinical trial performed in 237 centers in China,5,535 type 2 diabetic patients inadequately controlled by previous therapies were treated with a stable metformin/sitagliptin dual therapy for 20 weeks.The patients who did not reach the glycated hemoglobin A1c(HbA1c) goal were then further randomized into glimepiride,gliclazide,repaglinide,or acarbose group for an additional 24-week triple therapy.A mean HbAlc reduction of 0.85%was observed when sitagliptin was added to the patients inadequately controlled with metformin in 16 weeks.Further HbAlc reductions in the 24-week triple therapy stage were 0.65%in glimepiride group,0.70%in gliclazide group,0.61%in repaglinide group,and 0.45%in acarbose group.The non-inferiority criterion for primary hypotheses was met for gliclazide and repaglinide,but not for acarbose,compared with glimepiride,when added to metformin/sitagliptin dual therapy.The incidences of adverse events(AEs) were 29.2%in the dual therapy stage and30.3%in the triple therapy stage.Metformin/sitagliptin as baseline therapy,with the addition of a third oral antihyperglycemic agent,including glimepiride,gliclazide,repaglinide,or acarbose,was effective,safe and well-tolerated for achieving an HbAlc<7.0%goal in type 2 diabetic patients inadequately controlled with previous therapies.The timely augmentation of up to three oral antihyperglycemic agents is valid and of important clinical benefit to prevent patients from exposure to unnecessarily prolonged hyperglycemia. | Wen Xu Yiming Mu Jiajun Zhao Dalong Zhu Qiuhe Ji Zhiguang Zhou Bin Yao Anhua Mao Samuel S.Engel Bin Zhao Yan Bi Longyi Zeng Xingwu Ran Juming Lu Linong Ji Wenying Yang Weiping Jia Jianping Weng | 2017 | Science China(Life Sciences)2017，60，3： | 19 |
| 2 | Prevalence of diabetes among menand women in China显示文摘 | Yang Wenying Lu Juming Weng Jianping Jia Weiping Ji Linong Xiao Jianzhong Shan Zhongyan Liu Jie Tian Ha- oming Ji Qiuhe Zhu Dalong Ge Jiapu Lin Lixiang Chen Li Guo Xiaohui Zhao Zhigang Li Qiang Zhou Zhiguang Shan Guangliang He Jiang | 2010 | N Engl J Med2010，362，： | 1 |
| 3 | Prevalence and associated factors of obstructive sleep apnea in hospitalized patients with type 2 diabetes in B eijing, C hina 对中国北京住院2型糖尿病患者的阻塞性睡眠呼吸暂停患病率的调查与相关因素分析显示文摘 | Rui Zhang Xiaohui Guo Lixin Guo Juming Lu Xianghai Zhou Linong Ji | 2015 | Journal of Diabetes2015，，： | 1 |
| 4 | Serum Lipids and Lipoproteins in Chinese Men and Women显示文摘 | Wenying Yang Jianzhong Xiao Zhaojun Yang Linong Ji Weiping Jia Jianping Weng Juming Lu Zhongyan Shan Jie Liu Haoming Tian Qiuhe Ji Dalong Zhu Jiapu Ge Lixiang Lin Li Chen Xiaohui Guo Zhigang Zhao Qiang Li Zhiguang Zhou Guangliang Shan Jiang He | 2012 | Circulation2012，，18： | 1 |
| 5 | Understanding the standard of care in the treatment of type 2 diabetes in China: results from a national survey显示文摘 | Ji Linong Julliana Newman Lu Juming Cai Xiaoling | 2014 | Chinese Medical Journal2014，，20： | 1 |
| 6 | Modedling method of constitutive law of rubber byperelasticity based on finite element simulations显示文摘 | WANG Linong LU Zhenhua | 2003 | Rubber Chemistry and Technology2003，79，1： | 1 |
| 7 | Melt rheological properties of reac- tive eompatibilized HDPE/PET blends 显示文摘 | LI Shucai LU Linong | 2008 | J Appl Polym Sci2008，108，6： | 1 |
| 8 | Cardiovascular risk profile and clinical characteristics of diabetic patients:a cross-sectional study in China显示文摘Background:Cardiovascular(CV)disease is the leading cause of morbidity and mortality in adults with type 2 diabetes(T2D).The aim of this study was to determine the CV risk in Chinese patients with T2D based on the 2019 European Society of Cardiology(ESC)and the European Association for the Study of Diabetes(EASD)guidelines on diabetes,pre-diabetes,and CV diseases.Methods:A total of 25,411 patients with T2D,who participated in the study of China Cardiometabolic Registries 3B study,were included in our analysis.We assessed the proportions of patients in each CV risk category according to 2019 ESC/EASD guidelines.Results:Based on the 2019 ESC/EASD guidelines,16,663(65.6%),1895(7.5%),and 152(0.6%)of patients were included in'very high risk,''high risk,'and'moderate risk'categories,respectively.The proportions of patients in each category varied based on age,sex,body mass index,and duration.While 58.7%(9786/16,663)of elderly patients were classified to'very high risk'group,89.6%(3732/4165)of patients with obesity were divided into'very high risk'group.Almost all patients with a duration of diabetes>10 years had'very high risk'or'high risk.'However,6701(26.4%)of Chinese T2D patients,who had shorter duration,and one or two risk factors,could not be included in any category(the'unclear risk'category).Conclusions:In China,most patients with T2D have'very high'or'high'CV risk based on 2019 ESC/EASD guidelines.However,the risk of patients in'unclear risk'group needs to be further classified. | Fang Lyu Xiaoling Cai Chu Lin Tianpei Hong Xiaomei Zhang Juming Lu Xiaohui Guo Zhufeng Wang Huifang Xing Guizhi Zong Linong Ji | 2022 | Chinese Medical Journal2022，，3： | 0 |
| 9 | Lipid control in adult Chinese patients with type 2 diabetes:a retrospective analysis of time trends and geographic regional differences显示文摘To the Editor:Patients with type 2 diabetes have a higher risk of cardiovascular diseases(CVD),relative to people without diabetes.Patients with diabetes always exhibit lipid abnormalities.Rapid economic development and accelerated urbanization have also led to lifestyle changes that may have an influence on the lipid parameters of Chinese patients with diabetes.Given the significant differences in socioeconomic status in China,geographical variations were also observed in the prevalence,awareness,treatment,and control of dyslipidemia among individuals who were≥45 years old in the general Chinese population.[1]There is a lack of large-scale studies regarding time trends and geographical variations in lipid concentrations and lipid control among Chinese adults with type 2 diabetes.Therefore,we conducted a study on time trends and geographical variations in lipid concentrations and lipid control in this population using the China National HbA1c Surveillance System(CNHSS)database of adult Chinese outpatients with type 2 diabetes during 2009 to 2013.The Ethics Committee of the Chinese People Liberation Army General Hospital approved the study protocol.Informed consent was obtained from all the patients before they were interviewed and data collected. | Yanping Yuan Xianghai Zhou Juming Lu Xiaohui Guo Linong Ji | 2022 | Chinese Medical Journal2022，，3： | 0 |
| 10 | Trends and regional differences in glycemic control of patients with type 2 diabetes in China, 2009–2013显示文摘To the Editor:According to the International Diabetes Federation,China has been ranked first worldwide in terms of the prevalence of diabetes among people aged 20 to 79 years.[1]As a cornerstone in the management of patients with type 2 diabetes mellitus(T2DM),the level of glycemic control has changed considerably over the past decades.A multicenter observational study in North China showed that 45.82%of patients with T2DM met the glycated hemoglobin(HbA1c)control standard in 2017.[2]With the largest population of residents with T2DM,China is also faced with significant regional discrepancies in the rates of adequate glycemic control(HbA1c<7%),ranging from 25.9%in Shaanxi province[3]to 56.1%in Jiangsu province.[4]Indeed,previous studies in China were conducted for short periods of time,in a limited number of areas,and with relatively small sample sizes.Based on the data of the China National HbA1c Surveillance System study(CNHSS),this analysis aimed to investigate temporal trends and regional variations in glycemic control in T2DM patients in China from 2009 to 2013. | Jiayu Cheng Xianghai Zhou Juming Lu Xiaohui Guo Linong Ji | 2022 | Chinese Medical Journal2022，，13： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员